SPY330.30+3.33 1.02%
DIA272.81+1.37 0.50%
IXIC10,963.64+184.84 1.71%

Oppenheimer Maintains Outperform on ADMA Biologics, Lowers Price Target to $7

Oppenheimer maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $14 to $7.

Benzinga · 05/07/2020 14:13

Oppenheimer maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $14 to $7.